4-[4-((thiiran-2-yl)methylsulfonyl)phenoxy]benzamine hydrochloride salt | 1333379-23-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[4-((thiiran-2-yl)methylsulfonyl)phenoxy]benzamine hydrochloride salt
• 英文别名: 4-(4-((thiiran-2-ylmethyl)sulfonyl)phenoxy)aniline hydrochloride；ND-322；4-[4-((thiiran-2-yl)methylsulfonyl)phenoxy]benzamine hydrochloride；ND-322 hydrochloride；4-[4-(thiiran-2-ylmethylsulfonyl)phenoxy]aniline;hydrochloride
• CAS: 1333379-23-9
• 化学式: C₁₅H₁₅NO₃S₂*ClH
• 分子量: 357.882
• InChiKey: FOCZQHBXIUOIJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.37
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[4-((thiiran-2-yl)methylsulfonyl)phenoxy]benzamine hydrochloride salt 在 N-甲基吗啉 、 盐酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 49.0h， 生成 2-amino-N-[4-[4-(thiiran-2-ylmethylsulfonyl)phenoxy]phenyl]acetamide;hydrochloride
  参考文献：
  名称：

  Selective Water-Soluble Gelatinase Inhibitor Prodrugs

  摘要：

  SB-3CT (1), a selective and potent thiirane-based gelatinase inhibitor, is effective in animal models of cancer metastasis and stroke; however, it is limited by poor aqueous solubility and extensive metabolism. We addressed these issues by blocking the primary site of metabolism and capitalizing on a prodrug strategy to achieve >5000-fold increased solubility. The amide prodrugs were quantitatively hydrolyzed in human blood to a potent gelatinase inhibitor, ND-322 (3). The arginyl amide prodrug (ND-478, 5d) was metabolically stable in mouse, rat, and human liver microsomes. Both 5d and 3 were nonmutagenic in the Ames II mutagenicity assay. The prodrug 5d showed moderate clearance of 0.0582 L/min/kg, remained mostly in the extracellular fluid compartment (Vd = 0.0978 L/kg), and had a terminal half-life of >4 h. The prodrug 5d had superior pharmacokinetic properties than those of 3, making the thiirane class of selective gelatinase inhibitors suitable for intravenous administration in the treatment of acute gelatinase-dependent diseases.

  DOI：

  10.1021/jm200566e
• 作为产物：
  描述：

  对氟硝基苯 在 盐酸 、 caesium carbonate 、 溶剂黄146 、 三乙胺 、 硫脲 、 间氯过氧苯甲酸 、 锌 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 144.0h， 生成 4-[4-((thiiran-2-yl)methylsulfonyl)phenoxy]benzamine hydrochloride salt
  参考文献：
  名称：

  Selective Water-Soluble Gelatinase Inhibitor Prodrugs

  摘要：

  SB-3CT (1), a selective and potent thiirane-based gelatinase inhibitor, is effective in animal models of cancer metastasis and stroke; however, it is limited by poor aqueous solubility and extensive metabolism. We addressed these issues by blocking the primary site of metabolism and capitalizing on a prodrug strategy to achieve >5000-fold increased solubility. The amide prodrugs were quantitatively hydrolyzed in human blood to a potent gelatinase inhibitor, ND-322 (3). The arginyl amide prodrug (ND-478, 5d) was metabolically stable in mouse, rat, and human liver microsomes. Both 5d and 3 were nonmutagenic in the Ames II mutagenicity assay. The prodrug 5d showed moderate clearance of 0.0582 L/min/kg, remained mostly in the extracellular fluid compartment (Vd = 0.0978 L/kg), and had a terminal half-life of >4 h. The prodrug 5d had superior pharmacokinetic properties than those of 3, making the thiirane class of selective gelatinase inhibitors suitable for intravenous administration in the treatment of acute gelatinase-dependent diseases.

  DOI：

  10.1021/jm200566e

文献信息

• GELATINASE INHIBITORS AND PRODRUGS
  申请人：Chang Mayland

  公开号：US20130052184A1

  公开（公告）日：2013-02-28

  The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The disease, disorder, or condition can include, for example, stroke, neurological disorders, or ophthalmological disorders. The treatment can include administering a compound or composition described herein, thereby providing a prodrug compound that metabolizes to an active MMP inhibitor in vivo. The MMP inhibition can be selective inhibition, for example, selective inhibition of MMP-2, MMP-9, and/or MMP-14. Thus, the invention provides non-mutagenic prodrug compounds of the formulas described herein that result in the inhibition of MMPs upon in vivo administration.

  这项发明提供了用于治疗受基质金属蛋白酶（MMPs）调节的疾病、疾病或病况的化合物、组合物和方法。疾病、疾病或病况可以包括中风、神经系统疾病或眼科疾病等。治疗可以包括给予本文描述的化合物或组合物，从而提供在体内代谢为活性MMP抑制剂的前体化合物。MMP抑制可以是选择性抑制，例如对MMP-2、MMP-9和/或MMP-14的选择性抑制。因此，该发明提供了根据本文描述的公式的非致突变的前体化合物，该化合物在体内给予后导致MMP的抑制。
• <i>O</i>-Phenyl Carbamate and Phenyl Urea Thiiranes as Selective Matrix Metalloproteinase-2 Inhibitors that Cross the Blood–Brain Barrier
  作者：Major Gooyit、Wei Song、Kiran V. Mahasenan、Katerina Lichtenwalter、Mark A. Suckow、Valerie A. Schroeder、William R. Wolter、Shahriar Mobashery、Mayland Chang

  DOI：10.1021/jm401217d

  日期：2013.10.24

  Brain metastasis occurs in 20-40% of cancer patients. Treatment is mostly palliative, and the inability of most drugs to penetrate the brain presents one of the greatest challenges in the development of therapeutics for brain metastasis. Matrix metalloproteinase-2 (MMP-2) plays important roles in invasion and vascularization of the central nervous system and represents a potential target for treatment of brain metastasis. Carbonate, O-phenyl carbamate, urea, and N-phenyl carbamate derivatives of SB-3CT, a selective and potent gelatinase inhibitor, were synthesized and evaluated. The O-phenyl carbamate and urea variants were selective and potent inhibitors of MMP-2. Carbamate 5b was metabolized to the potent gelatinase inhibitor 2, which was present at therapeutic concentrations in the brain. In contrast, phenyl urea 6b crossed the blood-brain barrier, however, higher doses would result in therapeutic brain concentrations. Carbamate 5b and urea 6b show potential for intervention of MMP-2-dependent diseases such as brain metastasis.
• Synthesis of chiral ND-322, ND-364 and ND-364 derivatives as selective inhibitors of human gelatinase
  作者：Yugang Yan、Xueying Chen、Xinying Yang、Jian Zhang、Wenfang Xu、Yingjie Zhang

  DOI：10.1016/j.bmc.2015.09.013

  日期：2015.10

  Compounds 10 (ND-322) and 15 (ND-364) are potent selective inhibitors for gelatinases, matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9). However, both of them are racemates. Herein we report facile synthesis of optically active (R)- and (S)-enantiomers of compounds 10 and 15. And the sulfonyl of 15 was transformed to sulfinyl to obtain four epimeric mixtures. All synthesized thiirane-based compounds were evaluated in MMP2 and MMP9 inhibitory assays. Our results indicated that the configuration of thiirane moiety had little effects on gelatinase inhibition, but the substitution of sulfinyl for sulfonyl was detrimental to gelatinase inhibition. Besides, all target compounds exhibited no inhibition against other two Zn2+ dependant metalloproteases, aminopeptidase N (APN) and histone deacetylases (HDACs), which confirmed the unique Zn2+ chelation mechanism of thiirane moiety against gelatinases. (c) 2015 Elsevier Ltd. All rights reserved.
• US8937151B2
  申请人：——

  公开号：US8937151B2

  公开（公告）日：2015-01-20
• US9321754B2
  申请人：——

  公开号：US9321754B2

  公开（公告）日：2016-04-26